Odanacatib

Odanacatib
220px
Systematic (IUPAC) name
N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide
Identifiers
CAS number 603139-19-1
ATC code None
PubChem CID 10152654
Chemical data
Formula C25H27F4N3O3S 
Mol. mass 525.56 g/mol
SMILES eMolecules & PubChem
Synonyms (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
Therapeutic considerations
Pregnancy cat.  ?
Legal status  ?
Routes oral

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis[1]. It is an inhibitor of cathepsin K,[2] an enzyme involved in bone resorption.

It is being developed by Merck & Co. As of November 2009, Merck is conducting phase III clinical trials.

References

  1. Template:Pmid
  2. Gauthier JY, Chauret N, Cromlish W, et al. (February 2008). [Expression error: Missing operand for > "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K"]. Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527. 

Template:Drugs for treatment of bone diseasesTemplate:Pharma-stub

  • Currently 0.00/5

Rating: 0.0/5 (0 votes cast) login to rate

Add to Favorite Print This Page Publish on Twitter
Bookmark and Share
close about Number of comments per page:
Time format: relative absolute
You need JavaScript enabled for viewing comments